Treating vestibular disorders with a molecule derived from bee venom

par | Oct 8, 2020

Claire Hellio, Professeure des Universités à l’Université de Bretagne Occidentale (UBO), et Marc Antonini, Directeur de recherche au Laboratoire d’Informatique, Signaux et Systèmes de Sophia Antipolis, ont reçu le 14 novembre la médaille de l’innovation du CNRS.

Back to news

SATT Sud-Est grants an operating license on a patent jointly owned by Aix-Marseille University and the CNRS, and takes a stake in the capital of the young start-up Vertidiag, which specializes in inner ear pathologies.

Vertidiag_Internal Ear

Launched in Marseille in early 2020, the biotech start-up Vertidiag is developing two therapeutic solutions covering the entire spectrum of vestibular disorders. Its flagship project is the development of an antivertiginous drug using a molecule derived from bee venom from the team of Drs Christian CHABBERT, CNRS Research Fellow, and Dr Brahim TIGHILET, Senior Lecturer Aix-Marseille University, researchers at the Laboratory of Sensory and Cognitive Neurosciences (LNSC UMR 7260 Aix-Marseille University, CNRS), both co-founders and scientific consultants of Vertidiag. Preclinical studies show that the administration of this compound significantly reduces the vertiginous syndrome without side effects. Vertidiag 's ambition is to address a public health issue: to relieve hospital congestion, provide appropriate solutions for patients and reduce healthcare costs related to inner ear pathologies.

Logotype_VERTIDIAG

Currently, in France, vertigo is the subject of 300,000 consultations per week, i.e. more than 15 million consultations per year; vertigo alone represents 5% of hospital emergency room consultations. Moreover, until now, these disorders were treated exclusively by default. It is precisely on this point that Vertidiag finds its strength; the molecule studied would make it possible to directly target the source of the problem.

Vertidiag is the result of public research and is supported by theinter-university incubator Impulse, SATT Sud-Est, which has just acquired a stake in the start-up, and Bpifrance in the framework of a French Tech Emergence grant. It is made up of a team of excellence in the field of inner ear pathologies and which capitalizes on a multidisciplinary approach to them. The company is managed by Nicolas CHANUT, co-founder and President of Vertidiag.

Portrait_Equipe_VERTIDIAG

The Vertidiag team in January 2020 at Weréso. Christian CHABBERT, Co-Founder and Scientific Consultant; Nicolas CHANUT, Co-Founder and President; Bérénice HATAT, Research Officer; Khaled ABDALLAH, Research Engineer and Project Manager; Romain BOULARAND, Assistant Engineer (L&D). 2020 Weréso Marseille. HD on request.

More info

 

Twitter

@SATTse_ @univamu @CNRS @incubimpulse @Bpifrance

 

 

 

 

 

 

 

 

 

 

Moving from invention to innovation is a wonder. And we're lucky, it's what we do.

Find out how SATT South-East accelerates technology transfer by bringing together research and business players. From patents to operating licences, including proof of concept, SATT Sud-Est is a key player in the South and Corsica regions in the field of innovation.

Headquarters
Le Silo, 35 Quai du Lazaret, CS 70545
13304 Marseille Cedex 02

The South-East SATT
Project financed with the support of the European Union with the European Regional Development Fund.